The ongoing COVID-19 pandemic greatly exposed a dearth of essential medications and significant vulnerabilities in the United States medical supply chain. Phlow Corporation aims to mitigate those weaknesses and manufacture essential generic medications at its Virginia manufacturing facility.
As one of the world’s top bio hubs, the BioHealth Capital Region (BHCR) is rife with life science assets. The region has been at the forefront of the SARS-CoV-2 vaccine race and it is rapidly becoming a center for advanced manufacturing. The BHCR cell and gene therapy ecosystem is thriving, and the area boasts one of the richest and most diverse tapestries of life science talent and workforce development programming. What’s more, Maryland, Washington, DC, and Virginia are home to several dynamic university systems that keep the talent and tech transfer pipeline humming and full.
Leading Children’s Hospitals and Phlow Corp. form an Unprecedented Coalition to Deliver Essential Medicines to Address Pediatric Drug Shortages RICHMOND, Va., March 18, 2021 – Phlow Corp., a U.S.-based, public benefit [….]
Phlow Corp. and USP announce strategic alliance focused on Pharmaceutical Continuous Manufacturing to increase supply of essential medicines for U.S. patients Richmond, VA., February 22, 2021 – Phlow Corp., a public [….]
Pharmaceutical manufacturer Civica Inc. will invest $124.5 million to establish its first in-house pharmaceutical manufacturing operation in the City of Petersburg, VA. The project will create 186 new jobs.
Five BioHealth Capital Region Companies Make List of Largest COVID-19 Government Contracts At BioBuzz, we’ve been chronicling the BioHealth Capital Region’s contributions to the battle against the coronavirus pandemic. We’ve [….]
